Abstract: The predominant DRMs for non-nucleoside reverse transcriptase inhibitors (NNRTIs) and nucleoside reverse transcriptase inhibitors (NRTIs) were V179D/E/A/DIN (13.60%) and M184V/I (1.44%), respectively, whereas only two major DRMs (M46L and I54L) were identified for protease inhibitors (PIs).
Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients.
PMID: 33722682
2021
International journal of infectious diseases
Abstract: DISCUSSION: Despite high prevalence of M184V/I in antiretroviral therapy (ART) experienced patients, DTG treatment outcomes will likely not be adversely affected by this mutation.
Abstract: DTG-based regimens have to great extent been effective at maintaining viral suppression in treatment experienced PLWH carrying M184V/I.
Abstract: High genetic barrier to the development of resistance associated with DTG and progressive viral suppression in patients switched to DTG-based therapy with M184V/I, may encourage better DTG outcomes and help in curbing increasing levels of HIV drug resistance in LMICs.
Abstract: Lamivudine and emtricitabine associated M184V/I mutation is highly prevalent in PLWH and the majority of HIV infected individuals receiving DTG regimen
Increased acquired protease inhibitor drug resistance mutations in minor HIV-1 quasispecies from infected patients suspected of failing on national second-line therapy in South Africa.
Abstract: Several RTI RAMs, such as K65R, M184V or K103N and PI RAM V82A, were identified in < 20% of the population.
Abstract: The majority of the drug resistance mutations in the minor viral quasispecies were observed in the V82A mutation (n = 13) in protease and K65R (n = 5), K103N (n = 7) and M184V (n = 5) in reverse transcriptase.
Result: Most of the DRMs in the minor viral quasispecies were observed in V82A mutation (n = 13) in protease and K65R (n = 5),
Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIV.
Abstract: CONCLUSIONS: In this real-world cohort, the majority of whom had virus with the M184V/I and >= 1 additional NA mutation, switching to DTG functional mono-or dual therapy with a non-cytosine NA resulted in persistent HIV-1 RNA >= 50 copies/mL in 18%.
Abstract: Historical genotypes indicated that all had an M184V/I, and 23 (59%) had an M184V/I and >= 1 additional NA mutation.
Introduction: In both the GEMINI and TANGO studies, patients with baseline nucleoside reverse transcriptase inhibitor (NRTI) resistance include those with M184V/I and integrase strand transfer inhibitor (INSTI) resistance were excluded.
Introduction: Prior reports have demonstrated a h
Long Dissociation of Bictegravir from HIV-1 Integrase-DNA Complexes.
PMID: 33649107
2021
Antimicrobial agents and chemotherapy
Introduction: Likewise, cases of failure with emergent M184V and R263K were reported for DTG-plus-lamivudine dual therapy in the clinical trials GEMINI and ACTG5353.
HIV Drug Resistance Mutations Detection by Next-Generation Sequencing during Antiretroviral Therapy Interruption in China.
Abstract: In 49 patients that followed-up a median 10 months later, HIV drug resistance mutations at >20% frequency such as K103N, M184VI and P225H still existed, but with decreased frequencies.
Result: Although these variants still existed at follow-up, the frequencies of the mutations M184VI, K103N and P225H decreased over time, and most of them remained at frequencies of more than 20%.
Result: At baseline, mutations with a frequency of 20% and above were NRTI-related, such as M184VI (2.0%, 1/49), and NNRTI-related like K103N (14.3%, 7/49), E138AG (4.1%, 2/49),
Low Frequency of Integrase Inhibitor Resistance Mutations Among Therapy-Naive HIV Patients in Southeast China.
PMID: 33679129
2021
Drug design, development and therapy
Abstract: Two samples harbored the T215S, M184V and K70E mutations related to nucleoside RTIs (NRTIs).
Result: In one participant, two NRTIs-resistance mutations (M184V, K70E) were observed.
Result: The M184V mutation can contribute to resistance if present along with other major resistance mutations high level resistance to lamivudine (3TC) and emtricitabine, and low-level resistance to didanosine and abacavir.
Table: M184V
A Novel High Throughput, Parallel Infection Assay for Determining the Replication Capacities of 346 Primary HIV-1 Isolates of the Zurich Primary HIV-1 Infection Study in Primary Cells.
Abstract: In this study, we established such an assay and validated it using 346 primary HIV-1 isolates from patients enrolled in the Zurich Primary HIV Infection study (ZPHI) and two control viruses, HIV-1 JR-CSFWT and HIV-1 JR-CSFK65R_M184V.
Result: Furthermore, HIV-1 JR-CSFWT replicates at a higher efficiency when compared to the replication kinetics of HIV-1 JR-CSFK65R_M184V (Figure 3D,E).
Result: HIV-1 JR-CSFK65R_M184V replicated more than 3-logs lower than HIV-1 JR-CSFWT.
Result: Interestingly, one primary HIV-1 isolate had a lower replication capacity than HIV-1 JR-CSFK65R_M184V.
Result: It has been previously shown that the K65R mutation reduces replication capacity up to 55% compared to the wildtype virus, but when paired with the
HIV-1 subtypes and drug resistance in children during antiretroviral therapy in Brazil.
Abstract: The most common primary mutations found were M184V (29.5%), K103N (25%), M41L (9.8%), T215Y (8.3%), and G190A (8.3%).
Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients.
PMID: 33734374
2021
The Journal of antimicrobial chemotherapy
Abstract: In December 2019, the remaining three subjects carrying M184V/I in pDNA maintained suppressed viraemia, and two still used emtricitabine in ART.
Abstract: METHODS: We included vertically HIV-infected youths/young adults aged >=10 years in the Madrid Cohort of HIV-1 Infected Children and Adolescents, exposed to lamivudine and/or emtricitabine, with M184V/I and/or K65R/E/N in historic plasma samples, on antiretroviral therapy (ART), virologically suppressed (HIV-1 RNA <50 copies/mL), and with available PBMCs in the Spanish HIV BioBank.
Abstract: Nine (75%) youths did not present M184V/I in pDNA after at least 1 year of viral suppression.
Abstract: OBJECTIVES: We analysed the prevalence of
ViMRT
HIV mutation literature information.
PMID: 
2022
HIV medicine
